NASDAQ:BCDA BioCardia Q3 2026 Earnings Date & Estimates $0.93 -0.06 (-6.37%) Closing price 04:00 PM EasternExtended Trading$0.99 +0.06 (+6.99%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. BioCardia is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026Conference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from BioCardia in Q3 2026BioCardia is expected to post earnings of -$0.15 per share. In the same quarter a year earlier BioCardia reported -$0.24 per share. BioCardia last reported on August 12, 2026, posting -$0.13 per share and beating the -$0.18 consensus estimate. BioCardia has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.15Prior-Year EPS-$0.24Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.13 (Beat by +$0.05)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report BioCardia Q3 2026 Earnings FAQ When does BioCardia report Q3 2026 earnings? BioCardia (NASDAQ:BCDA) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is BioCardia's Q3 2026 earnings call? BioCardia's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for BioCardia? Analysts expect BioCardia to post earnings of -$0.15 per share for Q3 2026. BioCardia Earnings HeadlinesBioCardia To Provide Update On CardiAMP HF II Study For HfrEF At HFSA ConferenceOctober 7, 2026 | rttnews.comBioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific MeetingOctober 7, 2026 | globenewswire.comElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.October 14 at 1:00 AM | Behind the Markets (Ad)BioCardia Files Revised FDA Submission For Helix Catheter; Premarket Stock UpOctober 2, 2026 | rttnews.comBioCardia Completes Revised FDA Pre-Submission for Helix Catheter Under De Novo PathwayOctober 1, 2026 | quiverquant.comQBioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ CatheterOctober 1, 2026 | globenewswire.comSee More BioCardia Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioCardia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCardia and other key companies, straight to your email. Email Address About BioCardiaBioCardia (NASDAQ:BCDA) is a biotechnology company focused on developing regenerative cell therapies and related delivery systems for cardiovascular diseases. The company’s programs are designed to repair or improve heart tissue and function in patients with conditions such as chronic heart failure and refractory angina caused by coronary artery disease. BioCardia’s lead programs include CardiAMP Cell Therapy, an investigational autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO, an investigational allogeneic cell therapy based on donor-derived cells. The company also develops catheter-based systems and procedures intended to deliver therapeutic cells to targeted areas of the heart. These products remain investigational and are being evaluated in clinical studies rather than marketed as broadly approved treatments. Founded in 2002 and headquartered in Sunnyvale, California, BioCardia conducts clinical development activities in the United States and has worked with medical centers and research collaborators internationally. The company is led by Peter Altman, who serves as president and chief executive officer.View BioCardia ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
